HealthDay News — For overweight and obese individuals, the Cardiometabolic Disease Staging (CMDS) score can quantify the risk of diabetes and predict the effectiveness of weight-loss therapy for preventing diabetes, according to research published in Diabetes Care.
Fangjian Guo, MD, PhD, from the University of Texas Medical Branch in Galveston, and W. Timothy Garvey, MD, from the University of Alabama at Birmingham, pooled data from 3040 overweight and obese participants in 3 randomized trials examining the efficacy and safety of phentermine/topiramate extended release (ER) for weight loss.
Overweight/obese adult patients were treated with a lifestyle intervention and randomized to either placebo or once-daily phentermine/topiramate ER in these trials. Baseline clinical data were used to calculate the weighted CMDS score.
The researchers found that the absolute decrease in 1-year diabetes incidence rates for subjects treated with medication vs placebo was greatest, intermediate, and small for those with high-risk CMDS scores, moderate CMDS risk, and low-risk CMDS scores, respectively (10.43% to 6.29%, 4.67% to 2.37%, and 1.51% to 0.50%, respectively). Over a 56-week period, for participants with baseline CMDS scores of ≥60, 30 to 59, and 0 to 29, the number of participants needed to treat to prevent one new case of diabetes was 24, 43, and 120, respectively.
“CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes,” the researchers write.
One author disclosed financial ties to the pharmaceutical industry.
Guo F, Garvey WT. Cardiometabolic disease staging predicts effectiveness of weight loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine/topiramate extended release [published online April 28, 2017]. Diabetes Care. doi: 10.2337/dc17-0088